R&D investments impact the corporate valuation in the healthcare industry, and the outbreak of COVID-19 influences their relationship. This paper applied simple linear regression to analyse the influence of R&D investments on corporate valuation among Chinese listed healthcare companies, showing an enormous difference between R&D intensity and personnel. R&D intensity will have a negative relationship with corporate valuation in the current year, while R&D personnel will positively influence it. Further, after the pandemic outbreak, the nexus between corporate valuation and R&D intensity transferred into positive, while its R&D personnel counterpart is still not significant. These results display that it is essential for Chinese listed healthcare companies to improve corporate valuation through altering their R&D policy, such as recruiting R&D personnel, paying attention to R&D investments and their effectiveness, and learning the experience from the epidemic outbreak. In addition, this paper also enriches the literature review of R&D spending and corporate valuation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.